New Study Shows Tapentadol Extended Release May Significantly Reduce Average Pain for Diabetic Peripheral Neuropathy

With more than 26 million people in the US living with diabetes, as reported by the Centers for Disease Control, approximately 60-70% of them will develop nerve damage called neuropathy at some point. New research has been published indicating that patients suffering with diabetic peripheral neuropathy (DPN) may experience a significant improvement in their pain when using an experimental pain medication – Tapentadol ER.  READ MORE

Source: PRNewswire